Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2016-08-12 Director's Dealing
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2016-08-12 English
FORM 4
Director's Dealing
2016-08-12 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-08-12 English
FORM 4
Director's Dealing
2016-08-12 English
OWNERSHIP DOCUMENT
Director's Dealing
2016-08-09 English
8-K 08.09.16
Board/Management Information Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated August 9, 2016. It includes two main items: Item 2.02, which furnishes the company's 2016 Second Quarter Financial Results press release (Exhibit 99.1), and Item 5.02, which announces the employment agreement of a senior executive, Dr. Douglas W. Losordo, confirming his continued role and compensation terms. The key content is the announcement of a change in senior management employment terms, which fits the category of Board/Management Information filings. The document is not the full financial report itself but a current report announcing operational results and management changes. Therefore, the best classification is MANG (Board/Management Information). The document length is about 4907 characters, which is sufficient to contain substantive information rather than a mere announcement or certification. Confidence is high due to clear identification of management appointment and employment agreement details.
2016-08-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.